Hematology

Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.

World Hemophilia Day spotlights the rare blood disorder that prevents the blood from clotting and can be dangerous when left untreated.

A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age populations, explains Tina Bhatnagar, DO.

A new meta-analysis finds patients who have CLL with “borderline” IGHV status have intermediate outcomes, supporting the need for more precise risk classification.

A real-world study has found that personalizing ibrutinib doses based on patient health does not compromise survival outcomes in chronic lymphocytic leukemia (CLL).

Posttransplant gilteritinib maintenance therapy may boost survival and reduce relapse in relapsed FLT3-mutated acute myeloid leukemia (AML), but larger trials are still needed.

Ajai Chari, MD, discusses the teclistamab-daratumumab approval, highlighting durable remissions, infection management, and the need for community oncologist uptake.

Zanubrutinib had low discontinuation and atrial fibrillation rates in R/R CLL/SLL, supporting tolerability over first-generation BTK inhibitors.

Learn how CRS and ICANS present in patients undergoing immunotherapy and what clinicians should know about recognizing and managing these toxicities.

The FDA proposes MRD negativity as an accelerated approval end point to speed access to novel myeloma therapies, says Nick Richardson, DO, MPH.

Adults can undergo CAR T-cell therapy for relapsed or refractory mantle cell lymphoma after the full approval of the treatment.

The FDA now permits outpatient monitoring for epcoritamab’s first full dose in R/R DLBCL, as EPCORE-NHL-6 data support safe bispecific antibody access.

Low serum IgE levels were independently associated with nearly double the risk of developing CLL in a retrospective cohort study of 118,740 adults.

Joseph Mikhael, MD, has spent decades advancing the treatment of multiple myeloma, and he’s been witness to a remarkable shift in outcomes among older adults.

It may be possible to detect Richter transformation (RT) years before it actually occurs in patients with chronic or small lymphocytic leukemia, research indicates.

Racial and ethnic disparities in outcomes persist in acute myeloid leukemia, but such disparities may not be tied to the use of tyrosine kinase inhibitors, according to a new report.

The FDA approval of daratumumab and hyaluronidase-fihj for high-risk smoldering MM shifts care beyond watchful waiting, notes Peter Voorhees, MD.

Interim data from the EPCORE-NHL-6 trial show safety outcomes similar to those in the pivotal trial that led to approval for the bispecific T-cell–engaging antibody.

Population data reveal serious infections drive CLL hospital costs, clarifying morbidity and mortality in the hematologic cancer and its true economic consequences.

Oncology has never had more to offer, and yet it is straining under the weight of its own progress.

Although they covered diverse topics across the cancer continuum, the event’s 4 panel discussions shared a common focus on advancing more equitable and coordinated care.

Patients with chronic or small lymphocytic leukemia now have a variety of treatment options, although a new report found not every patient was presented with multiple options.

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and chemotoxicity.